The model's full reasoning — Q2 2023 call → NOWe need to evaluate two gates based on the transcript. Gate 1: Is the company talking about how demand is off the charts? And do the numbers support that claim? The transcript mentions "significant increase in demand" for KEDRAB, and "significant increase in our supply to Kedrion for further sales in the U.S. market." They also say "we anticipate even further momentum in the second half of the year." They don't explicitly say "off the charts" but they do say "significant increase" and "significant market share expansion." The numbers: they had revenue growth of 32% in first half, and KEDRAB sales increased. But is that "off the charts"? The transcript says "we experienced a significant increase in demand" and "we anticipate even further momentum." It's strong but not necessarily "off the charts." However, the gate asks if the company is talking about demand being off the charts. They don't use that exact phrase, but they do describe strong demand. The numbers: they had $16 million in KEDRAB revenue in 2022, and in first half 2023 they had significant increase. But we don't have exact numbers for KEDRAB alone. The overall revenue growth is 32%. That is strong but not necessarily "off the charts." The gate says "only consider the data i give you" meaning the transcript. The transcript does not explicitly say "off the charts." It says "significant increase" and "significant market share expansion." So I would say Gate 1 is not clearly yes. But let's read carefully: "we do experience a significant increase in demand, a significant increase in our supply to Kedrion for further sales in the U.S. market." That is strong but not "off the charts." The gate asks "is the company talking about how demand is off the charts?" They are not using that hyperbole. So I think Gate 1 is NO. But let's see if there is any other mention. They also say "we anticipate even further momentum." So it's positive but not extreme. So Gate 1 is likely NO. Gate 2: Improvement filter. The question is whether the claimed demand strength is materially attributable to industry-wide scarcity conditions. The transcript does not mention any shortages, capacity constraints, lead times, double-ordering, etc. Instead, they attribute the demand to their marketing efforts, collaboration with Kedrion, and product differentiation (on-label pediatric indication). They also mention market share gains.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TRP | TC Energy Corporation | Q1 2024 | 2024-05-03 | B |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C |
| ONON | On Holding AG | Q2 2022 | 2022-08-16 | A |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | A |
| CPAC | Cementos Pacasmayo S.A.A. | Q4 2021 | 2022-02-15 | C |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
ONON · Q2 2022 → YESThe question requires evaluating two gates independently based on the transcript, then returning YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows the company describing demand as exceptionally strong through record growth (67% YoY, CHF 291.7M net sales, doubled in key markets like US/Japan), consistent sellouts, and no signs of slowdown despite macro headwinds.
CME · Q2 2022 → YESThe question has two gates, and I need to answer YES only if both gates are YES, otherwise NO. And answer with exactly YES or NO. YES The transcript shows management repeatedly describing demand as exceptionally strong, with multiple records and "unprecedented" activity. Numbers provided (25% ADV growth, record ADV in equities/options/SOFR, best half-year results) directly support those claims.
CPAC · Q4 2021 → YESThe question requires evaluating two gates independently based on the transcript, then returning YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES ``` The transcript shows the company describing demand as "unprecedented" and "off the charts" through record volumes (2.6M tons in 2019 to 3.6M in 2021, ~38-40% growth) and revenue/EBITDA surges (49.